Galectin-3 as a biomarker in breast neoplasms: Mechanisms and applications in patient care

J Leukoc Biol. 2022 Nov;112(5):1041-1052. doi: 10.1002/JLB.5MR0822-673R. Epub 2022 Sep 20.

Abstract

Galectin-3 is a member of the lectin family encoded by the LGALS3 gene on chromosome 14. It is secreted by a wide range of immune cells and mammary tumor cells. Through its activity on the tumor microenvironment, in particular on tumor-infiltrating leukocytes, galectin-3 improves the proliferation, survival, and colonizing ability of mammary neoplastic cells. Consequently, galectin-3 expression in the tumor microenvironment could worsen therapeutic outcomes of breast neoplasms and become a biomarker and a therapeutic target in combined immunotherapy in breast neoplasms. There is a limited amount of information that is available on galectin-3 in breast cancer in Africa. In this review, we analyze how galectin-3 influences the tumor microenvironment and its potential as a biomarker and therapeutic target in breast neoplasms. We aim to emphasize the significance of investigating galectin-3 in breast neoplasms in Africa based on the results of studies conducted elsewhere.

Keywords: M2 macrophage; NK cell; TILs; immunotherapy; tumor microenvironment.

Publication types

  • Review

MeSH terms

  • Biomarkers
  • Breast Neoplasms* / diagnosis
  • Breast Neoplasms* / pathology
  • Female
  • Galectin 3* / genetics
  • Humans
  • Tumor Microenvironment

Substances

  • Biomarkers
  • Galectin 3